Praulent gets FDA nod for heart attack and stroke
The approval was based on data from ODYSSEY OUTCOMES.
Read More
Tag: alirocumab
EU regulators expand Praluent’s label
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Read More
Sanofi, Regeneron to cut price of Praluent
Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Read More
Sanofi/Regeneron unveil more positive data for PCSK9 inhibitor
Sanofi and Regeneron have unveiled new data further backing the safety and efficacy of PCSK9 inhibitor Praluent in lowering cholesterol in patients with diabetes.
Read More
Praluent slashes need for apheresis treatment
Sanofi/Regeneron’s cholesterol buster Praluent reduced the need for apheresis treatment in patients with very high cholesterol by 75 percent versus a placebo, show findings from the Phase III ODYSSEY ESCAPE trial.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
